Last reviewed · How we verify
Cerebral Dopamine Neurotrophic Factor
At a glance
| Generic name | Cerebral Dopamine Neurotrophic Factor |
|---|---|
| Also known as | CDNF |
| Sponsor | Herantis Pharma Plc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU (PHASE3)
- Biological and Psychological Health Effect of Ramadan Study
- Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study (PHASE1, PHASE2)
- Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cerebral Dopamine Neurotrophic Factor CI brief — competitive landscape report
- Cerebral Dopamine Neurotrophic Factor updates RSS · CI watch RSS
- Herantis Pharma Plc. portfolio CI